Th2 cell clonal anergy as a consequence of partial activation. - Wikidata - awgldk - TriplyDB

Th2 cell clonal anergy as a consequence of partial activation.

Th2 cell clonal anergy as a consequence of partial activation.

http://www.wikidata.org/entity/Q36363894

about

Different Levels of T-Cell Receptor Triggering Induce Distinct Functions in Hepatitis B and Hepatitis C Virus-Specific Human CD4+ T-Cell Clones Clonal anergy induced in a CD8+ hapten-specific cytotoxic T-cell clone by an altered hapten-peptide ligand Peptide-based molecular analyses of HLA class II-associated susceptibility to autoimmune diseases.The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis.Down-regulation of Th2 responses by Brucella abortus, a strong Th1 stimulus, correlates with alterations in the B7.2-CD28 pathway Peripheral T-cell tolerance defined through transgenic mouse studies.The contributions of T-cell anergy to peripheral T-cell tolerance.Convergence of Itch-induced ubiquitination with MEKK1-JNK signaling in Th2 tolerance and airway inflammation.T-cell tolerance and autoimmune diabetes.Decreased CD4 expression by polarized T helper 2 cells contributes to suboptimal TCR-induced phosphorylation and reduced Ca2+ signaling West Nile virus T-cell ligand sequences shared with other flaviviruses: a multitude of variant sequences as potential altered peptide ligands Antigen-specific inhibition of CD4(+) T-cell responses to β-lactoglobulin by its single amino acid-substituted mutant form through T-cell receptor antagonism.Cutaneous melanoma: therapeutic lymph node and elective lymph node dissections, lymphatic mapping, and sentinel lymph node biopsy.Modulation of T cell development by an endogenous altered peptide ligand Models of T cell anergy: is there a common molecular mechanism?Selective activation of the calcium signaling pathway by altered peptide ligands Persistence of peptide-induced CD4+ T cell anergy in vitro Copresentation of natural HIV-1 agonist and antagonist ligands fails to induce the T cell receptor signaling cascade.Cellular and molecular mechanisms of TSLP function in human allergic disorders--TSLP programs the "Th2 code" in dendritic cells.Antagonism of HIV-specific CD4+ T cells by C-terminal truncation of a minimum epitope.Transcriptional modulation of TCR, Notch and Wnt signaling pathways in SEB-anergized CD4+ T cells.Effects of vaccination with altered Peptide ligand on chronic pain in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis F(c)gammaRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires.Future therapeutics for the induction of peripheral immune tolerance in autoimmune disease and organ transplantation.Effects of immunomodulators on the response induced by vaccines against autoimmune diseases.Radically altered T cell receptor signaling in glycopeptide-specific T cell hybridoma induced by antigen with minimal differences in the glycan group.Peptide-mediated regulation of the allergic immune response.Manipulation of the Th1/Th2 cell balance: an approach to treat human autoimmune diseases?Nucleosome-driven autoimmune response in lupus. Pathogenic T helper cell epitopes and costimulatory signals.Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells.TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand.Magnitude of activity in chronic hepatitis C is influenced by apoptosis of T cells responsible for hepatitis C virus.T cell receptor-mediated signal transduction controlled by the beta chain transmembrane domain: apoptosis-deficient cells display unbalanced mitogen-activated protein kinases activities upon T cell receptor engagement.Requirement of CD28-CD86 costimulation for allergen-specific T cell proliferation and cytokine expression.Altered superantigenic ligands demonstrate the quantitative nature of T-cell activation.Partial T cell activation with an altered superantigenic ligand Effect of in vivo administration of anti-CTLA-4 monoclonal antibody and IL-12 on the induction of low-dose oral tolerance CD4 T cells in protection from influenza virus: Viral antigen specificity and functional potential

P2860

Q27469939-ABA38D53-25BB-4AFF-8493-65149EF53A67 Q28347348-3A8AE482-C0E5-4193-A529-1CDA9E28DA41 Q33536183-965CE964-A777-4A78-AF4A-E4983CE16EDA Q33554869-ED37B9B4-C472-4ECC-B06D-84087BF95473 Q34001670-FBCFCB02-7C66-4456-ABF6-90505808F1E4 Q34193042-85C3FEC0-F87D-4CE4-ACE4-72331167F620 Q34308870-58EAE5A8-9D8E-4438-8B24-1DA3C830B53F Q34468354-77E6FCF7-5D28-41A5-82A6-EE39A2368B99 Q34552317-4333CA34-A642-48E1-A856-9459EB4AF180 Q34562425-57E95504-21B7-45B0-9A84-B4A13A7084ED Q36155428-1E43A56F-C4E9-4EAA-89BF-D62CEDEF0125 Q36304701-E2D424BD-802D-4DFC-8BAF-1E9B72AE0A93 Q36317096-9F276B41-A315-4B02-9ACF-EA3F6349AAC2 Q36364377-D8FDB0DC-15D0-4E24-9245-4AC4E45A6C1F Q36366967-A4A35AC8-52E6-4490-AF3B-D3A7E3105CE3 Q36367455-6CF61FE2-E136-45BB-A947-EAAE0A95AF65 Q36381014-64F5CA99-99E9-4986-A534-A89087DA603E Q36475932-4EDA239D-88C3-4F13-8722-57FE1E06E681 Q36865256-C44F1290-1B19-447D-A54B-98C4CC6BF021 Q36923916-311DF4C4-0E67-44BC-801B-5084B106F803 Q36995457-2E6CC503-3608-45D8-A76C-1D8D97C96F39 Q37261686-55F54D89-7652-4B4B-B35B-D6588BECE79A Q37360991-BBB73618-73BA-4F01-B2E5-CB06FAAEBF4E Q37689611-BFAB921D-C0A4-40E4-A2F3-49B0B441F117 Q37773272-76244A95-7F54-4AA1-AEAF-DBB621516D61 Q40046753-27421293-9013-4728-B438-C9895915B87F Q40763215-6FBB46F0-A5C6-430C-992B-4CF6A19C6F27 Q40944867-F2040968-8BF3-4589-ADED-606D6BEF2ABC Q41167186-B92B8300-6EBC-48EB-B083-4CE56CCA5DB6 Q41500830-DB4EE4C8-A0FC-47DF-813A-C11E8DCFAC24 Q41853652-CAE60CB1-6502-4A1F-B2E6-9449F3AB0571 Q42972510-0A30F5F9-AFFC-471F-A47E-488D9EB06ECA Q42995594-04F521F4-F32D-453D-B257-5BB4AED26769 Q43810167-57ECA607-BF0C-46C0-8687-8C12A98C93D3 Q52904932-38754031-3664-4195-A27F-B5318A279357 Q53805171-BD69E22D-1F65-4A55-BA5C-051673CCDC8E Q56797388-9810B637-CEDE-4CB9-B613-CA20FDBC2DD4 Q56904161-06492514-DF26-46CA-A373-F25AE9C5FDCB Q57094380-7C0EC5FC-EC91-4CBA-AD52-63288F9B1960

P2860

Th2 cell clonal anergy as a consequence of partial activation.

http://www.wikidata.org/entity/Q36363894

description

1994 nî lūn-bûn

@nan

1994年の論文

@ja

1994年学术文章

@wuu

1994年学术文章

@zh-cn

1994年学术文章

@zh-hans

1994年学术文章

@zh-my

1994年学术文章

@zh-sg

1994年學術文章

@yue

1994年學術文章

@zh

1994年學術文章

@zh-hant

name

Th2 cell clonal anergy as a consequence of partial activation.

@ast

Th2 cell clonal anergy as a consequence of partial activation.

@en

type

label

Th2 cell clonal anergy as a consequence of partial activation.

@ast

Th2 cell clonal anergy as a consequence of partial activation.

@en

prefLabel

Th2 cell clonal anergy as a consequence of partial activation.

@ast

Th2 cell clonal anergy as a consequence of partial activation.

@en

P1433

Q36363894-ECDAEDBE-32D4-4D18-BE64-0144BAC40EFF

P1476

Q36363894-7E93E672-D33B-40F7-A875-85DAC2EA692D

P2093

Q36363894-19E99EEB-9C6A-49BC-89F8-645659C86886

Q36363894-5C77AE5B-0476-440C-89F8-CCD2ECDF5172

Q36363894-E9AAA20D-D4EA-47FF-AEFE-E5156F69C0D1

P2860

Q36363894-0035E6E2-4995-4AFA-9E8C-0C32893480F0

Q36363894-08F7023C-24DF-4AF1-AD9D-F57C5D8A1074

Q36363894-0D2B117D-3378-4A97-9A4D-F135C05F8EA5

Q36363894-1BD16179-211B-4CF6-B251-18289DA2105F

Q36363894-1E8DA63C-56D2-466F-A603-7504721959C6

Q36363894-23A39C05-9A83-478D-BE70-0883D04AB6D2

Q36363894-327E20F1-D6B7-440B-BE6F-45419674457A

Q36363894-3A62D960-255B-464B-B373-75094CF1732E

Q36363894-40C7889B-D967-423A-B1EE-9D2A0DEA84C9

Q36363894-4198E3EE-EEB3-4ADB-A9BB-C10AB0E30085

P304

Q36363894-500DCD9D-BD1E-4049-B272-F3DA0B089C93

P31

Q36363894-6EA9A17B-113C-4085-A0CF-4FDCB8A80B9F

P356

Q36363894-67829582-E905-4086-9CF9-01FD375E66C6

P407

Q36363894-9C0EA0B0-6EAF-4AC9-AE9E-49A4E0A7F06D

P433

Q36363894-968ACD9B-813F-454D-9DC4-BC9E816F592F

P478

Q36363894-7892EB4F-402E-47DA-9025-BEE543B4263F

P577

Q36363894-50CD70AC-CA4B-4AB9-9A28-70934C969A4B

P5875

Q36363894-72C4E0E9-DCBD-41B2-84EB-15AAFF2F98C6

P698

Q36363894-C1C1212E-23A4-4B27-B5BF-E6DAA734DAF7

P932

Q36363894-7EB2E036-D22F-4E0B-A516-4C927E3C0B1E

P356

P1433

Journal of Experimental Medicine

P1476

Th2 cell clonal anergy as a consequence of partial activation.

@en

P2093

B D Evavold

http://www.w3.org/2001/XMLSchema#string

J Sloan-Lancaster

http://www.w3.org/2001/XMLSchema#string

P M Allen

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation

CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones

Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins

T helper cell subsets require the expression of distinct costimulatory signals by antigen-presenting cells.

Differential regulation of interleukin 4 and interleukin 5 gene expression: a comparison of T-cell gene induction by anti-CD3 antibody or by exogenous lymphokines.

Role of interleukin 1 in the activation of T lymphocytes

Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation

Identification of a monoclonal antibody specific for a murine T3 polypeptide.

Antagonism of superantigen-stimulated helper T-cell clones and hybridomas by altered peptide ligand.

CTLA-4 is a second receptor for the B cell activation antigen B7

P304

1195-1205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.180.4.1195

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

180

http://www.w3.org/2001/XMLSchema#string

P577

1994-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

15268294

http://www.w3.org/2001/XMLSchema#string

P698

7931057

http://www.w3.org/2001/XMLSchema#string

P932

2191705

http://www.w3.org/2001/XMLSchema#string